Nootropics Index - Save on smarter supplements
Nootropics>Synthetic nootropics & research compounds>Levetiracetam
Synthetic nootropics & research compounds

Levetiracetam

Levetiracetam

Levetiracetam is a U.S. prescription antiseizure medicine, not a dietary supplement or a nootropic. Limited exploratory cognitive findings in heterogeneous clinical populations do not establish healthy-user enhancement. Its U.S. label carries important behavioral, psychiatric, impairment, renal-adjustment, withdrawal, and rare DRESS warnings; an online-pharmacy listing is not evidence of lawful or authentic supply.

Isolated CompoundSyntheticClinical ResearchLimited Human EvidencePopulation Specific EvidenceHigh Risk ProfileSedation Risk
Updated August 2026/5 min read/5 citations
Reviewed by the NootropicsIndex editorial team.Method: prioritize cited human research and official safety or regulatory sources; compare retailer-listed prices without endorsing products.Affiliate disclosure
Extra caution

Who should avoid this or get expert review first

This is not a recommendation to use. These groups should treat the profile as a reason to slow down and verify safety, rules, and personal context.

  • Ordinary prescription use2The baseline risk is high because U.S. authoritative prescribing information applies at ordinary prescription use and includes behavioral or psychiatric reactions, impairment, withdrawal risk, and rare potentially severe hypersensitivity. Severity varies and many effects may improve with clinical management, but the next lower level would understate the prescription-medicine safety burden for people exposed to the drug.
01

What is it?

Cognition evidence remains limited and population-specific4
A 2024 meta-analysis of 16 placebo-controlled trials reported an exploratory executive-function signal in heterogeneous clinical populations. Potential publication bias and population differences mean it does not establish healthy-user cognitive enhancement.

What is Levetiracetam?

2

Levetiracetam is a synthetic prescription antiseizure medicine, not a dietary supplement. Its chemical class alone does not establish a consumer cognitive benefit.

02

Names, aliases and forms

Common NameLevetiracetam
Brand NamesKeppra; Keppra XR; Spritam; Elepsia XR
Research CodesUCB-L059; UCB 22059
Iupac Name(2S)-2-(2-oxopyrrolidin-1-yl)butanamide
Chemical Name(S)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide
Cas Number102767-28-2
Pubchem Cid5284583
Molecular FormulaC8H14N2O2
InchikeyHPHUVLMMVZITSG-LURJTMIESA-N
Regulatory NamesUNII 44YRR34555; ATC N03AX14
03

Potential effects and evidence map

A 2024 meta-analysis reported an exploratory executive-function signal in heterogeneous clinical populations, with potential publication bias and no basis for healthy-user nootropic enhancement. U.S. FDA labeling concerns prescription antiseizure use and safety, not a consumer cognitive product.

Effect domainMagnitudeGrade
Focus / attention4
UnknownConfidence: Low

A 2024 meta-analysis found an exploratory executive-function signal in heterogeneous clinical populations; it does not establish focus or attention enhancement for healthy users.

Note Potential publication bias and population differences limit inference beyond the studied clinical settings.

1/5
D
Memory / learning4
UnknownConfidence: High

The cited review does not establish memory or learning enhancement for healthy users.

Note Population-specific research is not a basis for consumer cognitive use.

0/5
E
Mood / wellbeing2
UnknownConfidence: High

No mood-support role is established; U.S. prescribing information instead highlights behavioral and psychiatric adverse reactions.

Note Safety information should not be reframed as mood evidence.

0/5
E
Calm / relaxation2
UnknownConfidence: High

Somnolence or altered alertness from a prescription medicine is not evidence of a calm or relaxation benefit.

Note U.S. prescribing information frames these as safety effects.

0/5
E
04

Typical dosages and timing

Dose context2Clinician-managed

U.S. prescribing information uses indication- and renal-function-specific dose selection. This profile does not present a self-directed dose, timing, or cycle.

05

Timing & effect horizon

Effect horizonUnknown
Unknown
Half-life2Acute
7 hours
Half-life is pharmacokinetic context2

U.S. prescribing information lists an adult plasma The time for blood levels to fall by half during the final elimination phase.Source of about 7 hours and renal elimination. This pharmacokinetic fact does not establish a consumer timing schedule.

06

Safety, side effects and risk profile

Sedation / impairment2
Confidence: High

Somnolence, fatigue, coordination difficulty, abnormal gait, and dizziness can impair driving or machinery use.

Note DailyMed advises monitoring and caution with driving/machinery until individual response is known.

4/5
A
Headache / dizziness2
Confidence: High

Headache and dizziness are common practical adverse-effect concerns, alongside Weakness or lack of energy and strength.Source and fatigue.

Note Keep separate from any perceived nootropic effect.

3/5
A
Dependence / withdrawal risk2
Confidence: High

Abrupt discontinuation can increase seizure risk; label guidance calls for gradual withdrawal.

Note This applies especially to people with epilepsy or seizure susceptibility.

4/5
A
Liver / kidney caution2
Confidence: High

Renal function affects clearance and dosing. U.S. prescribing information also includes serious hypersensitivity warnings that can involve internal organs.

Note The high score reflects prescription-medicine safety at ordinary labeled use, not a claim about a dietary supplement.

4/5
A
Interaction risk2
Confidence: Medium

Levetiracetam has relatively low pharmacokinetic interaction potential, but renal function and concurrent antiseizure prescriptions remain clinician-managed context.

Note Low pharmacokinetic interaction potential does not turn a prescription medicine into a self-directed supplement.

2/5
B
Pregnancy / lactation caution2
Confidence: Medium

Pregnancy and lactation require specialist management because seizure control, fetal/infant exposure, and dose changes must be balanced clinically.

Note Avoid simplistic avoid/use language; this is a medical management issue.

4/5
B
Legal / regulatory risk2
Confidence: High

In the United States, DailyMed prescribing information describes levetiracetam products as prescription medicines rather than dietary supplements.

Note Prescription, import, and pharmacy requirements vary by jurisdiction; the legacy row does not verify lawful availability or authenticity.

5/5
A
Evidence uncertainty4
Confidence: High

Cognitive findings are exploratory and population-specific, while healthy-user nootropic benefit is not established.

Note This uncertainty is about consumer cognitive use, not the evidence base for prescribed antiseizure use.

3/5
E
Core safety context2Behavioral risk

U.S. prescribing information describes behavioral abnormalities and psychotic symptoms, including aggression, agitation, anxiety, depression, hostility, irritability, and suicidal thoughts or behavior.

Hypersensitivity3Rare, potentially severe

In 2023, the U.S. FDA strengthened warnings about Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), a rare multiorgan hypersensitivity reaction reported with levetiracetam.

Impairment2Driving caution

Somnolence, fatigue, coordination difficulty, abnormal gait, headache, and dizziness are listed practical adverse-effect concerns. U.S. prescribing information cautions that driving or machinery can be affected until individual response is known.

Discontinuation2Gradual withdrawal

U.S. prescribing information states that levetiracetam should be withdrawn gradually because abrupt discontinuation can increase seizure frequency.

07

Interactions and cautions

Interaction context2

Levetiracetam has relatively low pharmacokinetic interaction potential, but renal function and concurrent antiseizure prescriptions remain part of the U.S. prescribing context. That does not support unsupervised use or changes.

08

Legal and regulatory status

United States, as of 2026-08-212

United States FDA and DailyMed prescribing information, accessed 2026-08-21, describes levetiracetam products as prescription medicines rather than dietary supplements. Prescription validity, importation, and pharmacy requirements vary by country and local jurisdiction.

09

How it compares

Racetam context1

Levetiracetam is structurally related to some racetam compounds, but structural relatedness does not establish the same benefits, safety profile, or legal status. Its public context is prescription medicine safety rather than casual nootropic comparison.

10

Practical buying and quality notes

  • The legacy online-pharmacy-style row has no captured strength, quantity, price, or dose. It cannot establish a comparable price, lawful availability, prescription validity, or product authenticity.5
  • A medication listing needs country-specific prescription and pharmacy controls, plus verified formulation and manufacturer information. Those controls are distinct from supplement price-comparison signals such as serving math or COAs.2
11

FAQ

Is levetiracetam a nootropic?

4

No established healthy-user nootropic benefit is shown. The cited 2024 review found only an exploratory executive-function signal in heterogeneous clinical populations, with limitations that make consumer extrapolation unsuitable.

Does this page provide a levetiracetam dose?

2

No. U.S. dose selection is indication- and renal-function-specific within prescription care, so this page does not provide a consumer dose or cycle.

How long does levetiracetam last?

2

U.S. prescribing information lists an adult plasma half-life of about 7 hours with renal elimination. This is pharmacokinetic context, not a self-timing instruction.

Why is mood risk emphasized?

2

U.S. prescribing information highlights behavioral abnormalities, psychotic symptoms, and suicidal thoughts or behavior. These safety findings are not evidence of mood support.

Why does the page mention gradual withdrawal?

2

The U.S. label identifies gradual withdrawal as a safety concern because abrupt interruption can increase seizure frequency.

12

References

  1. PubChem. Levetiracetam (CID 5284583): identity, molecular formula, synonyms, and identifiers. Accessed 2026-08-21.
  2. DailyMed. KEPPRA (levetiracetam) tablets and oral solution: U.S. prescribing information, setid 3ca9df05-a506-4ec8-a4fe-320f1219ab21. Accessed 2026-08-21.
  3. U.S. Food and Drug Administration. FDA warns of rare but serious drug reaction to antiseizure medicines levetiracetam and clobazam. 2023-11-28. Accessed 2026-08-21.
  4. Lin C-Y, Chang M-C, Jhou H-J. Effect of Levetiracetam on Cognition: A Systematic Review and Meta-analysis of Double-Blind Randomized Placebo-Controlled Trials. CNS Drugs. 2024;38(1):1-14. doi:10.1007/s40263-023-01058-9. PMID: 38102532.
  5. NootropicsIndex legacy product-listing snapshot: Levetiraceta (Keppra generic) via extrapharmacy.ru. Accessed internally before 2026-08-21.
Note

This page is informational and summarizes available evidence. It is not medical advice, a recommendation, or a substitute for guidance from a qualified clinician.